Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048516 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing)
A Phase 3 study of Renal Insufficiency, Chronic, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 68
- Enrollment target
- 18
- Study locations
NCT00048516 is a Phase 3 study of Renal Insufficiency, Chronic that has completed, run by Abbott. The registered enrollment target is 68 participants, below the 645-participant average among 14 other Renal Insufficiency, Chronic trials with a reported enrollment target (89% lower). The trial reports 18 study locations across 13 states.
The verdict
NCT00048516, a Phase 3 study of Renal Insufficiency, Chronic, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 68 participants
- Enrollment target
- 18
- Study locations
Study Summary
The objective of this study is to determine whether paricalcitol is safe and effective compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney disease.
Conditions Studied
Interventions
- DRUG paricalcitol capsule
Study Locations (18)
California
- VA Greater Los Angeles Healthcare System, West Los Angeles - Los Angeles
- Nephrology Associates Medical Group - Riverside
- Kidney Center, Inc. - Simi Valley
Colorado
- Denver Nephrologists - Denver
- University of CO Health Sciences Center - Denver
New York
- Long Island College Hospital - Brooklyn
- Erie County Medical Center - Buffalo
Other
- Wojewodzki Szpital Specjalistyczny AM w Bialymstoku - Bialymstoku
- Krakow Hospital - Krakow
Iowa
- Dialysis PC - Des Moines
Minnesota
- Twin Cities Clinical Research - Arden Hills
Pennsylvania
- Temple University Hospital - Philadelphia
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2002-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00048516
The ClinicalTrials.gov registry entry for NCT00048516 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 645-participant average among 14 other Renal Insufficiency, Chronic trials with a reported enrollment target (89% lower). The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Insufficiency, Chronic appearing as the primary indexed condition, and to 1 intervention - of which paricalcitol capsule is the first listed.
NCT00048516 reports 18 study locations spanning 13 distinct geographic areas - top geographies include California, Colorado, New York.
Frequently Asked Questions
What is clinical trial NCT00048516 about?
NCT00048516 is a clinical study titled "Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing)". The objective of this study is to determine whether paricalcitol is safe and effective compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney disease.
What is the current status of trial NCT00048516?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 68 participants. The study started on 2002-02.
What conditions does trial NCT00048516 study?
This clinical trial studies the following conditions: Renal Insufficiency, Chronic.
What interventions are being tested in trial NCT00048516?
The interventions under investigation include: paricalcitol capsule (DRUG).
Who is sponsoring clinical trial NCT00048516?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00048516 being conducted?
This trial has 18 study locations across California, Colorado, Iowa, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Insufficiency, Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of Zemplar Capsule in Reducing Serum IPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)
COMPLETED · Phase 3
-
Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease
COMPLETED · Phase 3
-
Neurovascular Transduction During Exercise in Chronic Kidney Disease
RECRUITING · Phase 2
-
Transformative Research in Diabetic Nephropathy 2.0
RECRUITING
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
Penn Produce Prescription and Chronic Kidney Disease Study
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.